Understanding the science behind Immuno-Oncology

Using the body's natural immune response to fight cancer

Contents

Revealing the potential of the immune system in cancer

Introduction to the tumor microenvironment and the immune response

The immune system is able to recognize **foreign threats (nonself)** as distinct from **normal cells (self).**[1-3] Innate and adaptive immunity act as complementary networks of self-defense against foreign threats, such as pathogens and cancer.[4]

In cancer, normal cells have mutated into tumor cells and are recognized as nonself by both the innate and adaptive immune systems.[5,6]

Antitumor activity of the innate and adaptive immune responses

Innate immune response

The first line of defense. It rapidly identifies and attacks tumor cells without antigen specificity.[4,5,7] It recognizes activating and inhibitory signals from target cells to distinguish self from nonself.[8-10] **NK cells** are the main effector cells of the innate immune system.[11,12]

Adaptive immune response

An antigen-specific and durable response.[4,7] Once activated, it can be sustained through immune memory.[13] **Cytotoxic T cells** are effector cells of the adaptive immune system.[4]

Key stages of the antitumor immune response

In both the innate and adaptive immune responses, immune cells have the potential to recognize and eliminate tumor cells. There are **3 principal stages** in this process:

Presentation ⟶ Infiltration ⟶ Elimination

Presentation

The innate immune system rapidly identifies and attacks tumor cells. Tumor cell death releases tumor antigens, which can activate the cytotoxic T cells of the adaptive immune system.[14,15]

Infiltration

Tumor antigens and other factors attract immune cells to the tumor site, where they invade and attack.[14]

Elimination

Activated cytotoxic T cells recognize tumor cells as the source of the antigen and target them for elimination.[14]

Tumor cells can evade and suppress immune activity

The complex network of activating and inhibitory pathways enables the antitumor immune response to detect and eliminate tumor cells at any point in tumor development.[16] However, tumors seek to evade or suppress the body's natural ability to eliminate cancer, and they can evolve at any phase of growth to "outsmart" the antitumor immune response.[16,17]

The tumor microenvironment consists of different cell types that help tumor cells evade antitumor immune activity.[18,19] As tumors evolve, they can influence the activation and composition of cells within the tumor microenvironment.[17]

Immune pathways combine to refine response

The 3 stages of the immune response—presentation, infiltration, and elimination—are regulated through a network of **activating** and **inhibitory** signaling pathways that **combine to maintain immune balance**.[3,14,20] Establishing fundamental stages of immune response that are impaired within noninflamed tumors is a strategy to improve the broad potential of I-O.

Various components of the immune system and the tumor microenvironment, including APCs, immune regulatory cells, stromal cells, and the tumor itself, regulate the ability of effector cells to eliminate tumors.[3,20-22] Ongoing I-O research at Bristol Myers Squibb is exploring how targeting these components, either alone or in combination, may restore the body's natural ability to fight cancer.

> **Deep insight into tumor-intrinsic signaling and immune biology continues to inform and inspire discoveries—enabling the development of novel combination therapies.**

Modulating a combination of signaling pathways can more efficiently promote antitumor activity than either pathway alone, as suggested by preclinical data.[23-27]

Select pathways that modulate tumor detection

Tumors use several mechanisms to avoid detection by the immune system.[28,29] Current research is investigating modulation of pathways, including those involved in antigen presentation and phagocytosis, to promote better tumor cell recognition.[28,29]

STING is an intracellular protein expressed in APCs such as DCs, which serves as an innate immune activator that stimulates APCs to drive cytotoxic T-cell activity.[30,31]

NLRP3 is a protein expressed in APCs, such as DCs, monocytes, and macrophages.[32] NLRP3 is involved in the assembly of the NLRP3 inflammasome, a protein complex that is a key mediator of innate immunity and the priming of T cells.[33,34]

FucGM1 is a ganglioside that is highly expressed on the surface of certain cancer cells and enables cell communication.[35-37]

Select pathways that modulate immunosuppression

Some tumors can avoid destruction by thriving in an immunosuppressive environment and dampening the immune response.[38,39] Current research is investigating modulation of pathways that regulate immunosuppressive activity in order to increase antitumor response.[38,39]

CTLA-4 is an immune checkpoint receptor on activated T cells and Tregs that inhibits T-cell activation.[40-42] Binding of CTLA-4 on cytotoxic T cells to CD80/86 on APCs inhibits T-cell activation.[43,44]

CCR2 and **CCR5** regulate the recruitment of immunosuppressive cells through the stroma.[45,46] CCR2 and CCR5 are both expressed on the surface of T cells, Tregs, monocytes, MDSCs, and TAMs.[47-52]

IL-8 is a cytokine produced by macrophages, monocytes, and stromal cells that promotes the recruitment of immunosuppressive MDSCs and, during the normal healing process, activates the angiogenic response to generate new blood vessels.[53-56]

Select pathways that modulate effector cell function

Various components of the immune system and tumor microenvironment regulate effector cell ability to eliminate tumors.[28,57] Current research is investigating the following pathways involved in the regulation of effector cells in order to enhance their activity.[28,57]

PD-1 is an immune checkpoint receptor on cytotoxic T cells that plays a key role in T-cell exhaustion and prevention of autoimmunity.[58-62]

CTLA-4 is an immune checkpoint receptor that, in addition to being expressed on activated T cells, is also found on Tregs, where it is a key driver of their ability to suppress the immune response. Tumor cells utilize the CTLA-4 pathway to suppress initiation of an immune response, decreasing T-cell activation and ability to proliferate into memory T cells.[21,40,41,44,63-65]

LAG-3 is an immune checkpoint receptor on the surface of both activated cytotoxic and regulatory T cells.[66-68] LAG-3 can negatively regulate T-cell proliferation and promote T-cell exhaustion.[69-71]

TIGIT is an immune checkpoint receptor expressed on the surface of cytotoxic and memory T cells, Tregs, and NK cells.[72,73] On all of these cells, TIGIT can play a role in immune suppression.[72-74]

TIM-3 is an immune checkpoint receptor involved in the suppression of both innate and adaptive immune cells.[75-77] It is expressed on the surface of a wide variety of immune cells, including cytotoxic T cells, Tregs, NK cells, and some APCs, such as DCs.[75,76]

SLAMF7 is an activating receptor on the surface of NK cells and other immune cells.[78] When engaged, SLAMF7 activates NK cells, the rapid responders of the immune system and the body's first line of defense against cancer.[5,79]

IL-2 is an activating receptor expressed on the surface of immune cells including cytotoxic T cells, NK cells, and Tregs.[80-83] The interaction of IL-2 with its receptor, IL-2R, promotes the activation and proliferation of various immune cells.[82,83]

OX40 is an activating, transmembrane receptor protein that is expressed on the surface of activated cytotoxic T cells and Tregs.[84-86] OX40 helps to create a tumor microenvironment more favorable to the antitumor immune response.[87-89]

IDO1 is an enzyme expressed in tumor cells and APCs.[90,91] It metabolizes tryptophan, an amino acid that is essential for T-cell survival, into immunosuppressive kynurenine, which normally acts as a counterbalance to suppress T cells and prevent overactivation of the immune response.[90,92-94]

Select tumor cell pathways

Various signaling and metabolic pathways intrinsic to tumor cells can drive oncogenesis and tumor growth.[95,96] Current research is investigating blocking these pathways in order to promote tumor cell death.[95,96]

BET is a family of proteins that are widely expressed and are responsible for regulating a variety of cellular processes.[97-100] In cancer, they upregulate the transcription of c-*Myc*, which is a major factor in the regulation of tumor proliferation.[101]

LSD1 is a demethylating enzyme that potentially plays a role in nucleosome remodeling, which may regulate genes critical to stem cell differentiation and cancer development.[102-104]

Discovering the possibilities of Immuno-Oncology biomarkers

Biomarkers in I-O research

With a focus on precision medicine, our research and development program aims to rapidly translate research into novel regimens to accelerate delivery of the right treatment, for the right patient, at the right time. Biomarkers are biologic molecules, cells, or processes found in tissues or body fluids (such as blood) that are a sign of a normal or abnormal process or disease.[105,106]

I-O biomarkers are a class of biomarker that can help evaluate an active antitumor immune response within the body.[107] I-O biomarkers can be prognostic, predictive, or pharmacodynamic, or a combination[108-111]:

Prognostic biomarkers may identify the likelihood of a clinical event, such as disease progression, disease recurrence, or death, independent of the therapy received.[108,109]

Predictive biomarkers may identify whether individuals are more likely to experience a favorable or unfavorable response to treatment.[108,109]

Pharmacodynamic biomarkers may show that a biologic response has occurred in an individual who has received treatment.[109,110]

> **As we continue to learn more about cancer biology—and with advancements in high-throughput technologies—the goal of I-O biomarker testing will be to provide actionable information toward developing personalized I-O therapy, including combinations with other treatment modalities.[112,113]**

Bristol Myers Squibb aims to identify clinical characteristics and I-O biomarkers to determine the patient populations most likely to benefit from I-O therapy.[112,114] I-O biomarker research aims to further characterize the unique interplay between the immune system and tumor cells in the following categories:

*Effector T cell or NK cell.

Tumor antigens

Tumor antigens are recognized as nonself or foreign by the host immune system and can initiate the adaptive immune response

TMB | MSI-H/dMMR

Inflamed tumors

Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment

PD-L1 | PD-L2 | TILs | Inflammation gene signatures

Immune suppression

Cells and proteins within the tumor and its microenvironment are associated with inhibition of the antitumor immune response

LAG-3 | Tregs | MDSCs

As I-O biomarkers are dynamic and complex, the presence or absence of any single I-O biomarker may not provide a complete understanding of the diverse interactions occurring within the tumor microenvironment.[114-116]

> **A composite I-O biomarker evaluation may provide a more comprehensive assessment of immune status.[114]**

Evolving clinical expectations in Immuno-Oncology

I-O is a different approach that fights cancer by targeting the immune system

Treatment approaches currently approved to fight cancer include chemotherapy, radiation, targeted therapy, and immunotherapy. Radiation, chemotherapy, and targeted therapy are all directed toward killing tumor cells.[117-120]

In contrast, I-O seeks to activate the body's natural immune response to fight cancer. This is a fundamentally different approach to cancer treatment.[121]

With this approach comes unique considerations and distinctive characteristics that continue to be researched, such as:

- Immune responses having the potential to deepen and sustain over time
- Resistance to immunotherapy, which can be present at the start of treatment or form over time
- Unique patterns of response, such as pseudoprogression
- Comprehensive endpoint considerations
- Immune-mediated adverse reactions

Resistance to immunotherapy can be present at the start of treatment or form over time

Advances in immunotherapy have resulted in enhanced antitumor responses. A significant challenge is the development of resistant disease and disease progression during or after therapy.[17,122]

As tumors evolve over time, they can influence the activation and composition of cells within the tumor microenvironment.[17,122] Some tumors do not respond from the beginning of treatment with immunotherapies, and this is termed "primary resistance." In contrast, "acquired resistance" describes tumors that initially respond to immunotherapies, but then fail to respond after a period of time.[123]

Identification of mechanisms of immunotherapy resistance is an area of research that will inform appropriate treatment options for patients.

> **Bristol Myers Squibb is committed to understanding the tumor immune response and exploring mechanisms underlying primary and secondary acquired resistance.**

Pseudoprogression may reflect development of antitumor immunity

The nature of the antitumor immune response can create the appearance of disease progression, either as tumor growth or appearance of new lesions.[124,125] This is known as pseudoprogression; this does not reflect tumor cell growth, but may be misclassified as disease progression.[124,126,127]

Baseline assessment	First assessment	Later assessment
Disease progression		
Pseudoprogression (nonconventional response)		

Tumors may **appear to grow or new lesions may appear when immune cells infiltrate the tumor site.**[124] Due to the time required to mount an adaptive immune response, pseudoprogression may also reflect continued tumor growth until a sufficient response develops.[124,128]

Pseudoprogression should be considered until disease progression can be confirmed

While uncommon, **pseudoprogression is an important consideration** when evaluating response to I-O therapies.[128] Histologic confirmation is not always possible, but close monitoring of the following factors may help identify pseudoprogression[124,127,129]:

	Disease progression	**Pseudoprogression** (nonconventional response)
Performance status	Deterioration of performance	Remains stable or improves
Systemic symptoms	Worsen	May or may not improve
Symptoms of tumor enlargement	Present	May or may not be present
Tumor burden		
Baseline	Increase	Initial increase followed by a response
New lesions	Appear and increase in size	Appear then remain stable and/or subsequently respond
Biopsy may reveal	Evidence of tumor growth	Evidence of immune-cell infiltration

Endpoint considerations for I-O research

The criteria currently used to assess potential benefit of cancer therapies are based on surgery, radiation therapy, and chemotherapy.[14] However, for **I-O**—a different way to fight cancer—a more comprehensive approach to endpoint assessment may be needed to recognize potential benefit.[131-135]

Overall survival (OS), **progression-free survival (PFS)**, and **overall response rate (ORR)** are among endpoints used to measure outcomes in oncology research. OS is the **gold standard** to assess therapeutic benefit when possible[136,137]

- In addition, key measures of response are **magnitude (size)**—measured as the proportion of patients with a predefined decrease in tumor burden, called the **ORR**—and **duration (time)**—assessed as the time from initial tumor response to disease progression, called the **duration of response (DOR)**[136]

- Finally, other measures such as **treatment-free survival (TFS)** and **patient-reported outcomes (PROs)** may also integrate a patient's QOL. TFS measures the time a patient spends off treatment, while incorporating QOL and toxicities experienced.[138,139] PROs evaluate the impact of treatment on QOL based on the patient's own account[140,141]

OS/PFS

Time Point Analyses	**Hazard Ratio/Relative Risk Reduction**	**Median Duration**
Estimate the presence or absence of sustained benefit at time points of interest (eg, 24 months)	Measures the magnitude of the difference between the two curves of a Kaplan-Meier plot	The time at which 50% of patients have either progressed or died

Assess potential benefit across the duration of the trial

Assess potential benefit at specific time points of interests

---

Assessing multiple measures can illustrate the full scope of clinical benefit.[132-134,142,143]

Assessment of these measures in combination can provide a broad and comprehensive picture of the difference between the investigational arm and the control arm with respect to PFS and OS.[132-134,142]

Immune responses have the potential to deepen and sustain over time

The immune response **evolves and expands** over time by constantly recognizing and remembering tumor antigens. This ability—to propagate and perpetuate—suggests the adaptive nature of the immune response.[14]

Immune responses are dynamic and have the potential to improve and deepen over time.[144,145]

Memory cell

Some cytotoxic T cells mature into memory T cells and provide long-term immunity

Cytotoxic T cell

APC

Tumor cell

Cytotoxic T cells recognize and kill tumor cells

Tumor cell death can release new antigens into tumor microenvironment

New antigens attract and activate new tumor antigen-specific T cells

Cycle propagates and perpetuates

As the immune response continues to expand, some cytotoxic T cells mature into memory T cells that may provide long-term immune protection, even if the original stimulus is no longer present.[13,145,146]

Immune-mediated adverse reactions

I-O therapies that modulate immune pathways may enable the immune system to attack healthy cells along with tumor cells. The effects are known as immune-mediated adverse reactions.[14,147-150]

When managing complications of immune-mediated adverse reactions, please consider:

- Patients, caregivers, and physicians should be educated to remain vigilant throughout and after I-O treatment to potentially minimize complications, some of which may be life–threatening[150,151]

- Treatment algorithms are available for use by healthcare providers to assist them in managing immune-mediated adverse reactions[152,153]

- Recent guidelines have been published that provide consensus recommendations for the management of immune-mediated adverse reactions.[153-155] Specific guidance for managing immune-mediated adverse reactions for an individual product can be found in the accompanying FDA-approved Prescribing Information[156]

> **As research in immunotherapy advances and more data are made available, understanding and effective management of immune-mediated adverse reactions will evolve.[156]**

Realizing the potential of Immuno-Oncology research

Depth of evidence for the immune response to cancer

Both solid tumors and hematologic malignancies are able to induce an immune response that can regulate their initial growth. This ability is known as **tumor immunogenicity.**[157,158] The body is able to recognize and attack cancer through the following stages of immune response:

Presentation

There is a broad range of tumors that are traditionally defined by high rates of mutations.[159] These mutations create neoantigens that can be recognized by the immune system, activating an antitumor immune response.[160]

Infiltration

Tumor-infiltrating immune cells are present in the tumor microenvironment. Their presence demonstrates their capacity to identify and migrate to tumor cells.[161-174]

Elimination

Early in their development, some tumors display evidence of spontaneous regression. This suggests that the immune system is able to recognize and eliminate some tumor cells and supports the concept that the body's own immune system has the ability to induce an antitumor response against cancer.[175]

Broad potential of I-O research

Evidence for tumor immunogenicity across a wide range of solid tumors and hematologic malignancies provides the rationale for the breadth of I-O research across tumor types[176]:

Tumor type*	Evidence for tumor immunogenicity		
	Presentation Presence of somatic mutations	**Infiltration** Evidence of immune-cell infiltration	**Elimination** Evidence of spontaneous regression
Bladder[159,171]	●	●	
Breast[173,177]	●	●	
Colorectal[172]	●	●	
Gastric/esophageal[164,178,179]	●	●	
Glioblastoma[160,162,180]	●	●	
Head and neck[165,181]	●	●	
Hepatocellular[169,182]	●	●	
Lung[159,164]	●	●	
Melanoma[159,164,175]	●	●	●
Ovarian[168,183]	●	●	
Pancreatic[172]	●	●	
Prostate[166,184]	●	●	
Renal[159,167]	●	●	●
Non-Hodgkin lymphoma[161,185,186]	●	●	●
Hodgkin lymphoma[170,187]	●	●	
Leukemia[188]	●		
Multiple myeloma[163,189]	●	●	

*List of tumors represents common types of cancer but is not exhaustive.

I-O research is constantly evolving

Some of the ongoing research at Bristol Myers Squibb focuses on:

- Building an understanding of the dynamic mechanisms that govern the immune system's response to cancer

- Understanding the role of immune signaling pathways, either alone or in combination, and how they can be modulated to restore the body's natural ability to fight cancer

- Identifying I-O biomarkers that clarify the unique interplay between the immune system and the tumor that may help to optimize personalized medicine and improve patient outcomes

- Developing a more comprehensive approach to endpoint assessment, to better recognize the potential benefit of I-O research

The potential of I-O research continues to expand, driven by the many patients with advanced cancer who await the offer of renewed hope and the potential of a longer life.

For more detailed information on the science behind I-O, please visit **IOHCP.com**.

References

1. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. *Science*. 1998;280(5361):243-248.

2. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. *J Clin Oncol*. 2004;22(6):1136-1151.

3. Leung J, Suh W-K. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. *Immune Netw*. 2014;14(6):265-276.

4. Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. *Allergy Asthma Clin Immunol*. 2011;7(suppl 1):S1. doi:10.1186/1710-1492-7-S1-S1.

5. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. *Cell Mol Immunol*. 2013;10(3):230-252.

6. Lu Y-C, Robbins PF. Cancer immunotherapy targeting neoantigens. *Semin Immunol*. 2016;28(1):22-27.

7. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. *Nat Rev Cancer*. 2004;4(1):11-22.

8. Bryceson YT, Ljunggren H-G, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. *Blood*. 2009;114(13):2657-2666.

9. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. *Immunology*. 2011;132(2):315-325.

10. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. *Nat Rev Immunol*. 2015;15:243-254.

11. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. *Science*. 2011;331(6013):44-49.

12. Gismondi A, Stabile H, Nisti P, Santoni A. Effector functions of natural killer cell subsets in the control of hematological malignancies. *Front Immunol*. 2015;6:567. doi:10.3389/fimmu.2015.00567.

13. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. *Nature*. 1994;369(6482):648-652.

14. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. 2013;39:1-10. doi:10.1016/j.immuni.2013.07.012.

15. Liu C, Lou Y, Lizée G, et al. Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice. *J Clin Invest*. 2008;118(3):1165-1175.

16. Zhang Q, Zhu B, Li Y. Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. *Front Immunol*. 2017;8:71. doi:10.3389/fimmu.2017.00071.

17. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity*. 2013;39(4):782-795.

18. Chen F, Zhuang X, Lin L, et al. New horizons in tumor microenvironment biology: challenges and opportunities. *BMC Med*. 2015;13:45. doi:10.1186/s12916-015-0278-7.

19. Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. *Oncoimmunology*. 2016;5(3):e1086862. doi:10.1080/2162402X.2015.1086862.

20. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. *Annu Rev Immunol*. 2013;31:227-258.

21. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat Rev Cancer*. 2015;15(8):457-472.

22. Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. *Nat Rev Clin Oncol.* 2016;13(3):143-158.

23. Chen S, Lee LF, Fisher TS, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. *Cancer Immunol Res.* 2014;3(2):149-160.

24. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. *J Transl Med.* 2014. doi:10.1186/1479-5876-12-36.

25. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proc Natl Acad Sci USA.* 2010;107(9):4275-4280.

26. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res.* 2011;72(4):917-927.

27. Singh M, Vianden C, Cantwell MJ, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. *Nat Commun.* 2017;8(1):1447.

28. Gonzalez H et al. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev.* 2018;32:1267-1284.

29. Disis ML. Mechanism of action of immunotherapy. *Semin Oncol.* 2014;41(suppl 5):S3-S13.

30. Barber GN. STING-dependent cytosolic DNA sensing pathways. *Trends Immunol.* 2014;35(2):88-93.

31. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. *J Clin Invest*. 2016;126(7):2404-2411.

32. Guarda G, Zenger M, Yazdi AS, et al. Differential expression of NLRP3 among hematopoietic cells. *J Immunol.* 2011;186(4):2529-2534.

33. Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. *Immunity*. 2015;43(4):751-763.

34. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. *Nat Med.* 2009;15(10):1170-1178.

35. Dickler MN, Ragupathi G, Liu NX, et al. Immunogenecity of fucosyl-GM1-keyhole limpit hemocyanin conjugate vaccine in patients with small cell lung cancer. *Clin Cancer Res.* 1999;5(10):2773-9.

36. Daniotti JL, Vilcaes AA, Torres Demichelis V, et al. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. *Front Oncol.* 2013;3:306.

37. Ponath P, Menezes D, Pan C, et al. A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer. *Clin Cancer Res.* 2018;24(20):5178-5189.

38. Shimizu K, Iyoda T, Okada M, et al. Immune suppression and reversal of the suppressive tumor microenvironment. *Int Immunol.* 2018;30(10):445-454.

39. Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. *Front Oncol.* 2018;8:315.

40. Perkins D, Wang Z, Donovan C, et al. Regulation of CTLA-4 expression during T cell activation. *J Immunol*. 1996;156(11):4154-4159.

41. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. *Front Immunol.* 2015. doi:10.3389/fimmu.2015.00418.

42. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13(4):227-242.

43. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *Am J Clin Oncol*. 2016;39(1):98-106.

44. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. *Eur J Immunol*. 1998;28(10):3137-3143.

45. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. *Cancer Lett*. 2014;352(1):36-53.

46. Huang B, Lei Z, Zhao J, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. *Cancer Lett*. 2007;252(1):86-92.

47. de Oliveira CEC, Oda JMM, Guembarovski RL, et al. CC chemokine receptor 5: the interface of host immunity and cancer. *Dis Markers*. 2014;2014:126954. doi:10.1155/2014/126954.

48. Lesokhin AM, Hohl TM, Kitano S, et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. *Cancer Res*. 2012;72(4):876-886.

49. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. *J Immunol*. 2008;180(1):122-129.

50. Mack M, Cihak J, Simonis C, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. *J Immunol*. 2001;166(7):4697-4704.

51. Sica A, Saccani A, Bottazzi B, et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. *J Immunol*. 2000;164(2):733-738.

52. Umansky V, Blattner C, Gebhardt C, Utikal J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. *Cancer Immunol Immunother*. 2017;66(8):1015-1023.

53. Duque GA, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. *Front Immunol*. 2014;5:491. doi:10.3389/fimmu.2014.00491.

54. Alfaro C, Teijeira A, Oñate C, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). *Clin Cancer Res*. 2016;22(15):3924-3936.

55. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. *Clin Cancer Res*. 2008;14(21):6735-6741.

56. David JM, Dominguez C, Hamilton DH, Palena C. The IL-8/IL-8R axis: a double agent in tumor immune resistance. *Vaccines (Basel)*. 2016;4(3). doi:10.3390/vaccines4030022.

57. Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. *J Hematol Oncol*. 2018;11(1):39.

58. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med*. 2000;192(7):1027-1034.

59. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol*. 2001;2(3):261-268.

60. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. *Blood*. 2009;114(8):1537-1544.

61. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*. 2006;439(7077):682-687.

62. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science*. 2001;291(5502):319-322.

63. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252-264.

64. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008;322(5899):271-275.

65. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J Exp Med*. 2000;192(2):303-309.

66. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. *Immunity*. 2004;21(4):503-513.

67. Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3–encoded protein: a new ligand for human leukocyte antigen class II antigens. *J Exp Med*. 1992;176(2):327-337.

68. Deng W-W, Mao L, Yu G-T, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. *Oncoimmunology*. 2016;5(11):e1239005. doi:10.1080/2162402X.2016.1239005.

69. Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali AA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. *J Immunol*. 2004;172(9):5450-5455.

70. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol*. 2009;10(1):29-37.

71. Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. *J Immunol*. 2013;190(9):4899-4909.

72. Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat Immunol*. 2009;10(1):48-57.

73. Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. *Proc Natl Acad Sci U S A*. 2009;106(42):17858-17863.

74. Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity*. 2014;40(4):569-581.

75. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. *Immunity*. 2016;44(5):989-1004.

76. Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. *Front Immunol*. 2013;4:449. doi:10.3389/fimmu.2013.00449.

77. Dardalhon V, Anderson AC, Karman J, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. *J Immunol*. 2010;185(3):1383-1392.

78. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. *J Immunol*. 2001;167(10):5517-5521.

79. Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. *Nat Immunol*. 2009;10(3):297-305.

80. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. *Immunity*. 2013;38(1):13-25.

81. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. *Immunity*. 2010;33(2):153-165.

82. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol*. 2012;12(3):180-190.

83. Nelson BH. IL-2, regulatory T cells, and tolerance. *J Immunol*. 2004;172(7):3983-3988.

84. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4 + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. *J Immunol.* 2001;167(12):6804-6811.

85. Ruby CE, Redmond WL, Haley D, Weinberg AD. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. *Eur J Immunol.* 2007;37(1):157-166.

86. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. *Blood.* 1997;89(12):4652-4658.

87. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. *J Exp Med.* 2008;205(4):825-839.

88. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. *J Immunol.* 2000;164:2160-2169.

89. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. *Cancer Res.* 2008;68(13):5206-5215.

90. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? *Immunol Today.* 1999;20(10):469-473.

91. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol.* 2004;4(10):762-774.

92. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. *Cancer Res.* 2012;72(21):5435-5440.

93. Routy JP, Routy B, Graziani GM, Mehraj V. The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy. *Int J Tryptophan Res.* 2016;9:67-77.

94. Mbongue JC, Nicholas DA, Torrez TW, Kim N-S, Firek AF, Langridge WHR. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. *Vaccines (Basel).* 2015;3(3):703-729.

95. National Cancer Institute. Cancer metabolism. https://ccr.cancer.gov/news/horizons/article/cell-metabolism-and-cancer. Accessed October 10, 2020.

96. Spranger S, Gajewski TF. Mechanisms of tumor cell-intrinsic immune evasion. *Annu Rev Cancer Biol.* 2018. 2:213–228.

97. Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. *Epigenetics.* 2017;12(5):323-339.

98. Fu L-L, Tian M, Li X, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. *Oncotarget.* 2015;6(8):5501-5516.

99. Zhu H, Bengsch F, Svoronos N, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. *Cell Rep.* 2016;16(11):2829-2837.

100. Sahai V, Redig AJ, Collier KA, et al. Targeting BET bromodomain proteins in solid tumors. *Oncotarget.* 2016;7(33):53997-54009.

101. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell.* 2011;146(6):904-917.

102. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502:480-488.

103. Maiques-Diaz A, Somervaille TCP. LSD1: biologic roles and therapeutic targeting. *Epigenomics.* 2016;8:1103-1116.

104. Hino S, Kohrogi K, Nakao M. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. *Cancer Sci.* 2016;107(9):1187–1192.

105. Henry NL, Hayes DF. Cancer biomarkers. *Mol Oncol.* 2012;6(2):140-146.

106. Strimbu K, Tavel JA. What are biomarkers? *Curr Opin HIV AIDS.* 2010;5(6):463-466.

107. Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? *Front Oncol*. 2013;3:1-8.

108. Ballman KV. Biomarker: predictive or prognostic? *J Clin Oncol*. 2015;33(33):3968-3971.

109. US Food and Drug Administration. About biomarkers. www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/Biomarker QualificationProgram/ucm535922.htm. Accessed August 1, 2017.

110. Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? *Clin Cancer Res*. 2014;20(10):2587-2594.

111. Kluger HM, Zito CR, Barr ML, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. *Clin Cancer Res*. 2015;21(13):3052-3060.

112. Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. *J Immunother Cancer*. 2016;4:3. doi:10.1186/s40425-016-0107-3.

113. Qiao M, Jiang T, Ren S, Zhou C. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: where do we stand? *Clin Lung Cancer*. 2018;19(1):1-11.

114. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015;348(6230):56-61.

115. Nelson D, Fisher S, Robinson B. The ''Trojan Horse'' approach to tumor immunotherapy: targeting the tumor microenvironment. *J Immunol Res*. 2014. doi:10.1155/2014/789069.

116. Blank CU, Haanen JB, Ribas A, Schumacher TN. The "cancer immunogram": visualizing the state of cancer-immune system interactions may spur personalized therapy. *Science*. 2016;352(6286):658-660.

117. Ricci MS, Zong W-X. Chemotherapeutic approaches for targeting cell death pathways. *Oncologist*. 2006;11(4):342-357.

118. Rich JN. Cancer stem cells in radiation resistance. *Cancer Res*. 2007;67(19):8980-8984.

119. Joo WD, Visintin I, Mor G. Targeted cancer therapy—are the days of systemic chemotherapy numbered? *Maturitas*. 2013;76(4):308-314.

120. Jones TS, Holland EC. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. *Oncogene*. 2012;31(16):1995-2006.

121. Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. *Nat Rev Drug Discov*. 2016;15(4):235-247.

122. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature*. 2017;541(7637):321-330.

123. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell*. 2017;168(4):707-723.

124. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*. 2009;15(23):7412-7420.

125. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. *AJNR Am J Neuroradiol*. 2011;32(11):1978-1985.

126. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. *J Clin Oncol*. 2015;33(31):3541-3543.

127. Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. *J Magn Reson Imaging*. 2018. doi:10.1002/jmri.26171.

128. Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. *Ann Oncol*. 2010;21:1944-1951.

129. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247.

130. Chen T-T. Statistical issues and challenges in immuno-oncology. *J Immunother Cancer*. 2013. doi:10.1186/2051-1426-1-18.

131. Scagliotti GV, Bironzo P, Vansteenkiste JF. Addressing the unmet need in lung cancer: the potential of immune-oncology. *Cancer Treat Rev*. 2015;41(6):465-475.

132. Friedman LM, et al. Survival analysis. In: *Fundamentals of Clinical Trials*. 4th ed. New York, NY: Springer; 2010:269-291.

133. Rich JT, Neely JG, Paniello RC, Voelker CCJ, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. *Otolaryngol Head Neck Surg*. 2010;143(3):331-336.

134. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. *Antimicrob Agents Chemother*. 2004;48(8):2787-2792.

135. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014;32(22):2380-2385.

136. Pazdur R. Endpoints for assessing drug activity in clinical trials. *Oncologist*. 2008;13(suppl 2):19-21.

137. Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. *Lancet Oncol*. 2015;16(1):e32-e42.

138. Regan MM, Werner L, Tarhini AA, et al. Treatment-free survival, a novel outcome applied to immuno-oncology agents in advanced melanoma. Poster presentation at ASCO 2018.

139. Gelber RD, Goldhirsch A, Cole BF, International Breast Cancer Study Group. Evaluation of effectiveness: Q-TWiST. *Cancer Treat Rev*. 1993;19:73-84.

140. LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care—hearing the patient voice at greater volume. *Nat Rev Clin Oncol*. 2017;14(12):763-772.

141. Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F. Endpoints in cancer clinical trials. *J Visc Surg*. 2014;151(1):17-22.

142. Brody T. Biostatistics. In: *Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines*. London: Academic Press; 2012:165-190.

143. US Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Published May 2007. Accessed November 13, 2018.

144. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. *Int Immunol*. 2001;13(5):625-632.

145. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. *Nat Rev Immunol*. 2002;2(4):251-262.

146. Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen. *J Immunol*. 1999;163(7):3676-3683.

147. Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol*. 2010;125(2 suppl 2):S3-23.

148. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol*. 2006;6(3):173-182.

149. Thangavelu G, Gill RG, Boon L, Ellestad KK, Anderson CC. Control of in vivo collateral damage generated by T cell immunity. *J Immunol*. 2013;191(4):1686-1691.

150. Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. *Blood*. 2011;118(3):499-509.

151. Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. *Immunotargets Ther*. 2017;6:51-71.

152. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander." *Toxins (Basel)*. 2014;6(3):914-933.

153. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018;36(17):1714-1768.

154. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol*. 2016;27(4):559-574.

155. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017;5:95.doi:10.1186/s40425-017-0300-z.

156. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med*. 2015;13:211. doi:10.1186/s12916-015-0455-8.

157. Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Hematological malignancies: at the forefront of immunotherapeutic innovation. *Nat Rev Cancer*. 2015;15(4):201-215.

158. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. *Nat Rev Cancer*. 2012;12(4):307-313.

159. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013;499(7457):214-218.

160. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumor immunity. *Nature*. 2014;512(7514):324-327.

161. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. *J Clin Oncol*. 2001;19(3):720-726.

162. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro Oncol*. 2015;17(8):1064-1075.

163. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. *Proc Natl Acad Sci U S A*. 2002;99(20):13009-13013.

164. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med*. 2015;21(8):938-945.

165. Heusinkveld M, Goedemans R, Briet RJP, et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. *Int J Cancer*. 2012;131(2):E74-E85.

166. Hussein M-R A, AL-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. *Exp Mol Pathol*. 2009;86(2):108-113.

167. Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. *Clin Dev Immunol*. 2010. doi:10.1155/2010/284581.

168. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. *Cancer Metastasis Rev*. 2011;30:141-151.

169. Liang J, Ding T, Guo Z-W, et al. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. *Br J Cancer*. 2013;109(4):1031-1039.

170. Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. *Hematol Oncol*. 2009;27(1):31-39.

171. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. *Proc Natl Acad Sci USA*. 2007;104(10):3967-3972.

172. Tran E, Ahmadzadeh M, Lu Y-C, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. *Science*. 2015;350(6266):1387-1390.

173. Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. *Br J Cancer*. 1990;62(6):971-975.

174. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol*. 2013;14(10):1014-1022.

175. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. *Melanoma Res*. 2009;19(5):275 282.

176. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. *Clin Cancer Res*. 2014;20(24):6258-6268.

177. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. *Science*. 2007;318(5853):1108-1113.

178. Tan D-J, Chang J, Liu L-L, et al. Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. *BMC Cancer*. 2006. doi:10.1186/1471-2407-6-93.

179. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. *Nat Genet*. 2012;44(5):570-574.

180. Bleeker FE, Lamba S, Zanon C, et al. Mutational profiling of kinases in glioblastoma. *BMC Cancer*. 2014. doi:10.1186/1471-2407-14-718.

181. Kass ES, Greiner JW, Kantor JA, et al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. *Cancer Res*. 2002;62(17):5049-5057.

182. Yin P-H, Wu C-C, Lin J-C, Chi C-W, Wei Y-H, Lee H-C. Somatic mutations of mitochondrial genome in hepatocellular carcinoma. *Mitochondrion*. 2010;10(2):174-182.

183. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474(7353):609-615.

184. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. *Nature*. 2011;470(7333):214-220.

185. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature*. 2011;476(7360):298-303.

186. Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. *Am J Hematol*. 1989;31(2):138-141.

187. Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. *Nat Genet*. 2014;46(4):329-335.

188. Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. *Blood*. 2014;124(3):453-462.

189. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. *Nat Rev Clin Oncol*. 2017;13(2):100-113.

Abbreviations

APC=antigen-presenting cell

BET=bromodomain and extraterminal domain

CCR2=chemokine (C-C motif) receptor 2

CCR5=chemokine (C-C motif) receptor 5

CTLA-4=cytotoxic T-lymphocyte antigen 4

DC=dendritic cell

dMMR=mismatch repair deficient

FucGM1=fucosyl GM1

IDO1=indoleamine 2,3-dioxygenase-1

IDO1=indoleamine 2,3-dioxygenase-1

Ig=immunoglobulin IL-2=interleukin-2

IL-8=interleukin-8 I-O=Immuno-Oncology

ITIM=immunoreceptor tyrosine-based inhibitory motif

LAG-3=lymphocyte-activation gene 3

LSD1=lysine-specific demethylase 1

MDSC=myeloid-derived suppressor cell

MHC=major histocompatibility complex

MSI-H=microsatellite instability-high

NK=natural killer

NLRP3=nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3

PD-1=programmed death receptor-1

PD-L1=programmed death ligand 1

PD-L2=programmed death ligand 2

QOL=quality of life

SLAMF7=signaling lymphocytic activation molecule family member 7

STING=stimulator of interferon genes

TAM=tumor-associated macrophage

TIGIT=T-cell immunoreceptor with Ig and ITIM domains

TIL=tumor-infiltrating lymphocyte

TIM-3=T-cell immunoglobulin mucin-3

TMB=tumor mutational burden

Treg=regulatory T cell

For more information, please visit
IOHCP.com

Bristol Myers Squibb™

Immuno-Oncology